Cargando…

Two postoperative chemotherapies for gastric cancer: FOLFOX4 vs. TPF

Clinical effects of FOLFOX4 and TPF chemotherapy regimen on postoperative gastric cancer patients were investigated. A total of 60 patients admitted to the First People's Hospital of Changzhou receiving gastric cancer operation were selected and they were divided into two groups at random. Thir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Honghu, Lu, Qicheng, Wang, Haitao, Zhu, Xianbo, Guan, Zhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312940/ https://www.ncbi.nlm.nih.gov/pubmed/30655850 http://dx.doi.org/10.3892/ol.2018.9695

Ejemplares similares

Silencing of UBE2D1 inhibited cell migration in gastric cancer, decreasing ubiquitination of SMAD4
por: Xie, Honghu, et al.
Publicado: (2021)

Increased response to TPF chemotherapy promotes immune escape in hypopharyngeal squamous cell carcinoma
por: Li, Ruichen, et al.
Publicado: (2023)

Effect of CADM1 on TPF-induced chemotherapy in laryngeal squamous cell carcinoma
por: Nie, Jiani, et al.
Publicado: (2023)

Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers
por: Bernadach, Maureen, et al.
Publicado: (2021)

Efficacy of Postoperative FOLFOX Versus XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Platelet–Lymphocyte Ratio in Patients Receiving XELOX
por: Yin, Xin, et al.
Publicado: (2020)

Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer
por: Jeon, Eun Kyoung, et al.
Publicado: (2011)

Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx - TPF-C-HIT
por: Jensen, Alexandra D, et al.
Publicado: (2011)

Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer
por: Li, Zi-Yu, et al.
Publicado: (2011)

FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer
por: CHEN, WENJUN, et al.
Publicado: (2014)

Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study
por: Hsieh, Ching-Yun, et al.
Publicado: (2020)

Neoadjuvant chemotherapy with different dose regimens of docetaxel, cisplatin and fluorouracil (TPF) for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
por: Jin, Ting, et al.
Publicado: (2017)

Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer
por: Zhao, Shen, et al.
Publicado: (2022)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients
por: Fayette, Jérôme, et al.
Publicado: (2016)

In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation
por: Jun, Michelle, et al.
Publicado: (2023)

Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma
por: Yang, Zhenyun, et al.
Publicado: (2023)

Comparison of TPF and TP Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma Based on TNM Stage and Pretreatment Systemic Immune-Inflammation Index
por: Xiong, Ying, et al.
Publicado: (2021)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Posterior Reversible Encephalopathy Syndrome Associated with FOLFOX Chemotherapy
por: Porcello Marrone, Luiz Carlos, et al.
Publicado: (2013)

FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
por: Lacombe, Caroline, et al.
Publicado: (2023)

Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study
por: Li, Shao-Hua, et al.
Publicado: (2023)

A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer
por: Wang, Xiang, et al.
Publicado: (2016)

POF (paclitaxel/oxaliplatin/5-fluorouracil/leucovorin) vs. SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial, FNF-014 trial
por: Su, Liyu, et al.
Publicado: (2022)

Efficacy and safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as perioperative chemotherapy treatments for resectable gastric cancer patients; a report from the middle east
por: Farrokhi, Pegah, et al.
Publicado: (2022)

Pulmonary Fibrosis Secondary to FOLFOX Chemotherapy: A Case Report
por: Soon, Wai Cheong, et al.
Publicado: (2014)

Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy
por: Okada, Shunji, et al.
Publicado: (2017)

Popliteal pseudoaneurysm after FOLFOX chemotherapy for metastatic colorectal cancer
por: Cosic, Luka, et al.
Publicado: (2019)

Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma
por: Zhong, Lai-ping, et al.
Publicado: (2015)

TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma
por: Leduc, Charlotte, et al.
Publicado: (2018)

Effect of FOLFOX4 combined with Brucea javanica emulsion on VEGF in patients with gastric cancer
por: Chen, Zheng, et al.
Publicado: (2018)

Flavonoids isolated from Tridax procumbens (TPF) inhibit osteoclasts differentiation and bone resorption
por: Al Mamun, Md. Abdullah, et al.
Publicado: (2015)

XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
por: Cassidy, J, et al.
Publicado: (2011)

Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma
por: Chen, Ruijuan, et al.
Publicado: (2021)

Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma
por: Shimanuki, Marie, et al.
Publicado: (2018)

Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy
por: Lee, Suee, et al.
Publicado: (2013)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting
por: Kim, Chee Young, et al.
Publicado: (2015)

Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer
por: Faure, Marjorie, et al.
Publicado: (2017)

Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer
por: Nguyen, T. Quang, et al.
Publicado: (2019)

Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei
por: Hiraide, Sakura, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qco7vion8tdpkj6js42fcbscf4